iRadimed (NASDAQ:IRMD) CEO Sells $321,337.50 in Stock

Key Points

• CEO sale: Roger Susi sold 3,750 shares for $321,337.50 at an average price of $85.69 on May 4 under a pre-arranged Rule 10b5-1 plan, reducing his stake by 0.17% to 2,191,250 shares (worth ~ $187.8M).
• Earnings beat and guidance: iRadimed reported Q1 EPS of $0.49 (vs. $0.46 expected) and $21.98M revenue, and set FY2026 guidance of $2.060–$2.210 EPS (consensus ~1.94); analysts maintain a consensus "Buy" rating with a $120 target.
• Dividend and market profile: The company declared a $0.20 quarterly dividend (annualized $0.80, 0.9% yield; ex-dividend May 15), trades near $86 with a ~$1.1B market cap and 92% institutional ownership, including recent increases by T. Rowe Price and Vanguard.

iRadimed Corporation (NASDAQ:IRMD - Get Free Report) CEO Roger Susi sold 3,750 shares of the stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $85.69, for a total transaction of $321,337.50. Following the sale, the chief executive officer directly owned 2,191,250 shares of the company's stock, valued at $187,768,212.50. This represents a 0.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

iRadimed Trading Up 0.4%

NASDAQ:IRMD traded up $0.34 on Wednesday, reaching $86.20. 39,699 shares of the stock traded hands, compared to its average volume of 87,238. The firm has a market capitalization of $1.10 billion, a price-to-earnings ratio of 47.10 and a beta of 0.90. The company's 50 day moving average is $96.34 and its 200-day moving average is $94.26. iRadimed Corporation has a 1-year low of $50.61 and a 1-year high of $107.90.

iRadimed (NASDAQ:IRMD - Get Free Report) last posted its quarterly earnings results on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.46 by $0.03. The firm had revenue of $21.98 million for the quarter, compared to analysts' expectations of $21.32 million. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. On average, equities research analysts forecast that iRadimed Corporation will post 1.94 EPS for the current fiscal year.

iRadimed Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 29th. Shareholders of record on Friday, May 15th will be issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Friday, May 15th. iRadimed's dividend payout ratio is presently 43.72%.

Hedge Funds Weigh In On iRadimed

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of iRadimed by 1.0% during the third quarter. Vanguard Group Inc. now owns 566,507 shares of the medical equipment provider's stock worth $40,313,000 after purchasing an additional 5,475 shares during the period. T. Rowe Price Investment Management Inc. raised its position in shares of iRadimed by 410.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider's stock worth $24,893,000 after purchasing an additional 205,783 shares during the period. Dimensional Fund Advisors LP raised its position in shares of iRadimed by 1.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 217,129 shares of the medical equipment provider's stock worth $21,123,000 after purchasing an additional 2,578 shares during the period. Goldman Sachs Group Inc. raised its position in shares of iRadimed by 37.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 205,227 shares of the medical equipment provider's stock worth $19,964,000 after purchasing an additional 55,426 shares during the period. Finally, State Street Corp raised its position in shares of iRadimed by 3.1% during the fourth quarter. State Street Corp now owns 192,952 shares of the medical equipment provider's stock worth $18,770,000 after purchasing an additional 5,713 shares during the period. 92.34% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on IRMD shares. Freedom Capital upgraded iRadimed to a "strong-buy" rating in a report on Thursday, April 2nd. Lake Street Capital restated a "buy" rating and set a $120.00 price target on shares of iRadimed in a report on Wednesday, February 11th. Finally, Roth Mkm restated a "buy" rating and set a $120.00 price target on shares of iRadimed in a report on Tuesday, February 10th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, iRadimed presently has a consensus rating of "Buy" and a consensus target price of $120.00.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.